Myovant Sciences rejects $2.5 billion takeover bid from Sumitovant, Sumitomo Pharma
Sumitovant, which currently holds approximately 52 per cent of the outstanding shares in Myovant Sciences, and Sumitomo Pharma,…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Myovant Sciences
Myovant Sciences and Pfizer announce US FDA acceptance of supplemental NDA for Myfembree
The US FDA set a target action date of 29th January, 2023 for this sNDA under the Prescription Drug User Fee Act (PDUFA)
Myovant Sciences and Accord Healthcare enter into exclusive licence agreement to commercialise…
Myovant to receive an upfront payment of $50 million, is eligible to receive commercial launch, sales-based and other milestones…